Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5903.074 | 1.0341 | 1.0636 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5903.074 | 0.5068 | 0.0615 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5903.074 | 0.5068 | 0.0615 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5903.074 | 0.1354 | -0.6898 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5903.074 | 0.1354 | -0.6898 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5903.074 | 0.0373 | -0.9068 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5903.074 | 0.0373 | -0.9068 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5903.074 | 0.0326 | -0.9178 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 5903.074 | 0.0326 | -0.9178 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5903.074 | 0.0258 | -0.9339 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 167 | uM | 5903.074 | 0.0258 | -0.9339 | 1.0729 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5904.074 | 1.1038 | 1.2154 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 5904.074 | 1.1038 | 1.2154 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5904.074 | 1.0165 | 1.0341 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 5904.074 | 1.0165 | 1.0341 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5904.074 | 0.9392 | 0.8741 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 5904.074 | 0.9392 | 0.8741 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5904.074 | 0.9886 | 0.9763 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 5904.074 | 0.9886 | 0.9763 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5904.074 | 0.3460 | -0.3340 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 5904.074 | 0.3460 | -0.3340 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5904.074 | 0.0820 | -0.8502 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 5904.074 | 0.0820 | -0.8502 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5904.074 | 0.0401 | -0.9286 | 0.9654 | |
| BT-20 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 5904.074 | 0.0401 | -0.9286 | 0.9654 |